Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.
暂无分享,去创建一个
Eric Stern | S. Kaech | T. Fahmy | W. Cui | E. Stern | Stacey L Demento | Tarek M Fahmy | Weiguo Cui | J. Criscione | Stacey L. Demento | Susan M Kaech | Jason M Criscione | Jacob Tulipan | Jacob Tulipan
[1] A. Altman,et al. Immunomodifiers in vaccines. , 1989, Advances in veterinary science and comparative medicine.
[2] E. Wherry,et al. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. , 2007, Immunity.
[3] S. Broderick,et al. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. , 2011, Biomaterials.
[4] Marcos Garcia-Fuentes,et al. Nanoparticles as protein and gene carriers to mucosal surfaces. , 2008, Nanomedicine.
[5] S. Kaech,et al. Generation of effector CD8+ T cells and their conversion to memory T cells , 2010, Immunological reviews.
[6] C. Figdor,et al. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. , 2011, Biomaterials.
[7] Naveen Palath,et al. Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo. , 2011, Vaccine.
[8] C. Kriegel,et al. Nanotechnology solutions for mucosal immunization. , 2010, Advanced drug delivery reviews.
[9] D. Keskin,et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. , 2011, Biomaterials.
[10] Yung-Fu Chang,et al. Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity. , 2009, Vaccine.
[11] P. Klenerman,et al. A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[12] P. Marrack,et al. Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.
[13] Nikhil S. Joshi,et al. Effects of Signal 3 during CD8 T cell priming: Bystander production of IL-12 enhances effector T cell expansion but promotes terminal differentiation. , 2009, Vaccine.
[14] C. Russell Middaugh,et al. Nanotechnology in vaccine delivery☆ , 2008, Advanced Drug Delivery Reviews.
[15] Yvonne Perrie,et al. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[16] Bali Pulendran,et al. Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development , 2006, Cell.
[17] T. Fahmy,et al. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. , 2011, Trends in biotechnology.
[18] N. Valiante,et al. Recent advances in the discovery and delivery of vaccine adjuvants , 2003, Nature Reviews Drug Discovery.
[19] Yong‐Chan Chung,et al. Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome. , 2002, Journal of biotechnology.
[20] PEG-PBLG nanoparticle-mediated HSV-TK/GCV gene therapy for oral squamous cell carcinoma. , 2008, Nanomedicine.
[21] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.
[22] S. Geary,et al. Nanoparticle Delivery Systems in Cancer Vaccines , 2011, Pharmaceutical Research.
[23] Y. Perrie,et al. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres , 2008, Journal of drug targeting.
[24] E. Unanue,et al. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. , 1991, Journal of immunology.
[25] Kendall A. Smith,et al. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. , 2010, Immunity.
[26] E. Fikrig,et al. TLR9-Targeted Biodegradable Nanoparticles as Immunization Vectors Protect against West Nile Encephalitis , 2010, The Journal of Immunology.
[27] R. Ahmed,et al. From vaccines to memory and back. , 2010, Immunity.
[28] T. Fahmy,et al. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. , 2010, Advanced drug delivery reviews.
[29] Sai T Reddy,et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.
[30] Bali Pulendran,et al. Immunological mechanisms of vaccination , 2011, Nature Immunology.
[31] A. Allison,et al. Liposomes as immunological adjuvants. , 1976, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[32] J. Harty,et al. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination , 2005, Nature Medicine.
[33] B. Adair. Nanoparticle vaccines against respiratory viruses , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[34] Sang-Jun Ha,et al. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. , 2006, Journal of immunology.
[35] Richard A Flavell,et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. , 2009, Vaccine.
[36] D. Irvine,et al. Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium vivax Malaria Vaccine , 2012, PloS one.
[37] R. Dudani,et al. Multiple Mechanisms Compensate to Enhance Tumor-Protective CD8+ T Cell Response in the Long-Term Despite Poor CD8+ T Cell Priming Initially: Comparison Between an Acute Versus a Chronic Intracellular Bacterium Expressing a Model Antigen1 , 2002, The Journal of Immunology.
[38] H. Merkle,et al. PEGylation as a tool for the biomedical engineering of surface modified microparticles. , 2008, Journal of pharmaceutical sciences.
[39] L. Bockenstedt,et al. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. , 2011, Biomaterials.
[40] G. Patel,et al. Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Mediated, and Memory Responses: Comparison to Conventional Liposomes and Alum , 2000, Infection and Immunity.
[41] D. Rahman,et al. Biodegradable microparticles as controlled release antigen delivery systems. , 1991, Immunology.
[42] Bhavna,et al. Potential of nanoparticulate drug delivery systems by intranasal administration. , 2010, Current pharmaceutical design.
[43] L. Lefrançois,et al. Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue , 2001, Science.
[44] R. Langer,et al. The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[45] Nikhil S. Joshi,et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. , 2007, Immunity.
[46] Ronald N Germain,et al. Vaccines and the future of human immunology. , 2010, Immunity.
[47] Wah Chiu,et al. Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.
[48] D. Birx,et al. Liposome‐stabilized oil‐in‐water emulsions as adjuvants: Increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen , 2004, Immunology and cell biology.
[49] I. Mellman,et al. Design opportunities for actively targeted nanoparticle vaccines. , 2008, Nanomedicine.